Lexipafant in severe acute pancreatitis: the final word?
Ulrich
C D
CD
Pancreatic Disease Center, Department of Internal Medicine, University of Cincinnati, Box 670595, 231 Albert B. Sabin Way, Cincinnati, OH 45267-0595, USA. charles.ulrich@uc.edu
D000818:Animals; D002986:Clinical Trials as Topic; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D007930:Leucine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D009102:Multiple Organ Failure / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D019283:Pancreatitis, Acute Necrotizing / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors* / Q000627:therapeutic use*; D012720:Severity of Illness Index
D007093:Imidazoles; D010972:Platelet Activating Factor; D007930:Leucine; C103289:lexipafant